Public Market Listing
Live quotes, historical charts, and market capitalization for Hangzhou Zhongmei Huadong Pharmaceutical are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(7 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1 receptorPeptide | Type 2 Diabetes | |
| Phase 3 | GLP-1 receptorSmall molecule | ObesityType 2 Diabetes | |
| Phase 3 | GLP-1/GIP receptor (dual)Peptide | ObesityType 2 Diabetes | |
janagliflozin(Huiyoujing) | Phase 3 | SGLT2Small molecule | Type 2 DiabetesChronic Kidney Disease |
| Phase 3 | JAK1 · JAK1Small molecule | Atopic Dermatitis | |
| Phase 1/2 | BCMACell therapy | Multiple Myeloma | |
| Phase 1 | FGFR2bAntibody–drug conjugate | Non-Small Cell Lung Cancer |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (4)
February 2027 (2)
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | — | — | $615M | — | report ↗ |
Hangzhou Zhongmei Huadong Pharmaceutical reported cash and equivalents of $614.64M for Q3 2025.
Figures only: this period's report disclosed no narrative text
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $6.1B | $244M | — | — | report ↗ |